Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Voriconazole: A second-generation triazole.

P. H. Chandrasekar1, E. Manavathu

  • 1Division of Infectious Diseases, Department of Medicine, Wayne State University School of Medicine, Detroit Medical Center Detroit, Michigan, USA.

Drugs of Today (Barcelona, Spain : 1998)
|June 5, 2003
PubMed
Summary

Voriconazole, a new antifungal triazole, shows promise against serious fungal infections like candidiasis and aspergillosis. However, potential resistance to voriconazole and other azoles requires careful monitoring.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023

Area of Science:

  • Mycology
  • Pharmacology

Background:

  • Voriconazole is a triazole antifungal agent.
  • It has a broad spectrum of activity against yeasts and filamentous fungi.
  • Voriconazole demonstrates fungicidal activity against Aspergillus species.

Purpose of the Study:

  • To evaluate the efficacy of voriconazole in treating fungal infections.
  • To assess the potential of voriconazole in managing candidiasis and aspergillosis.

Main Methods:

  • Review of preliminary data from animal models.
  • Analysis of clinical trial results.

Main Results:

  • Voriconazole shows promise in treating candidiasis and aspergillosis.
  • Development of resistance and cross-resistance with other azoles is a concern.

Related Experiment Videos

Conclusions:

  • Voriconazole is a valuable addition to antifungal therapies.
  • It offers a new option against potentially fatal fungal infections.
  • Monitoring for resistance is crucial.